MA43968A - Thérapie génique pour traiter la mucopolysaccharidose de type i - Google Patents
Thérapie génique pour traiter la mucopolysaccharidose de type iInfo
- Publication number
- MA43968A MA43968A MA043968A MA43968A MA43968A MA 43968 A MA43968 A MA 43968A MA 043968 A MA043968 A MA 043968A MA 43968 A MA43968 A MA 43968A MA 43968 A MA43968 A MA 43968A
- Authority
- MA
- Morocco
- Prior art keywords
- gene therapy
- mucopolysaccharidosis type
- treat mucopolysaccharidosis
- treat
- type
- Prior art date
Links
- 102100035028 Alpha-L-iduronidase Human genes 0.000 title 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 title 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 title 1
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290547P | 2016-02-03 | 2016-02-03 | |
| US201662323271P | 2016-04-15 | 2016-04-15 | |
| US201662337178P | 2016-05-16 | 2016-05-16 | |
| US201662367798P | 2016-07-28 | 2016-07-28 | |
| US201762452560P | 2017-01-31 | 2017-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43968A true MA43968A (fr) | 2018-12-12 |
Family
ID=58108727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043968A MA43968A (fr) | 2016-02-03 | 2017-02-02 | Thérapie génique pour traiter la mucopolysaccharidose de type i |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10973929B2 (fr) |
| EP (1) | EP3411488A1 (fr) |
| JP (2) | JP7360241B2 (fr) |
| KR (1) | KR20180121899A (fr) |
| AU (2) | AU2017215211C1 (fr) |
| BR (1) | BR112018015751A2 (fr) |
| CA (1) | CA3012195A1 (fr) |
| IL (1) | IL260959B1 (fr) |
| MA (1) | MA43968A (fr) |
| SG (2) | SG11201806270XA (fr) |
| WO (1) | WO2017136500A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102346455B1 (ko) | 2013-03-15 | 2022-01-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ｍｐｓｉ 치료를 위한 조성물 및 방법 |
| MA43968A (fr) | 2016-02-03 | 2018-12-12 | Univ Pennsylvania | Thérapie génique pour traiter la mucopolysaccharidose de type i |
| SG11201907714UA (en) | 2017-02-28 | 2019-09-27 | Univ Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| WO2018209205A1 (fr) | 2017-05-11 | 2018-11-15 | The Trustees Of The University Of Pennsylvania | Thérapie génique de céroïdes-lipofuscinoses neuronales |
| CA3068328A1 (fr) | 2017-07-06 | 2019-01-10 | The Trustees Of The University Of Pennsylvania | Therapie genique mediee par aav9 pour traiter la mucopolysaccharidose de type i |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| CN107699590A (zh) * | 2017-10-13 | 2018-02-16 | 成都中医药大学 | 一种制备重组人α‑L‑艾杜糖醛酸酶的方法 |
| KR20200104307A (ko) | 2017-11-30 | 2020-09-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 뮤코다당류증 iiia형에 대한 유전자 요법 |
| EP3717652A4 (fr) | 2017-11-30 | 2021-11-24 | The Trustees of the University of Pennsylvania | Thérapie génique pour mucopolysaccharidose de type iiib |
| SG11202100423YA (en) * | 2018-07-18 | 2021-02-25 | Regenxbio Inc | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idus) |
| EP3894864A2 (fr) * | 2018-12-10 | 2021-10-20 | Denali Therapeutics Inc. | Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation |
| WO2020162978A1 (fr) * | 2019-02-06 | 2020-08-13 | Sangamo Therapeutics, Inc. | Procédé de traitement des mucopolysaccharidoses de type i |
| AU2020369570A1 (en) * | 2019-10-23 | 2022-05-12 | The Trustees Of The University Of Pennsylvania | Compositions for DRG-specific reduction of transgene expression |
| EP4093428A1 (fr) * | 2020-01-22 | 2022-11-30 | RegenxBio Inc. | Traitement de la mucopolysaccharidose i avec une alpha-l-iduronidase glycosylée entièrement humaine (idua) |
| EP4096721A1 (fr) * | 2020-02-02 | 2022-12-07 | The Trustees of The University of Pennsylvania | Compositions utiles pour traiter la gm1 gan[[d]]gliosidose |
| US20230304034A1 (en) | 2020-05-12 | 2023-09-28 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| BR112023002904A2 (pt) * | 2020-08-26 | 2023-04-25 | Univ Pennsylvania | Vírus adenoassociado recombinante para tratar neurodegeneração com início na idade adulta associada a grn |
| US20230365955A1 (en) | 2020-10-09 | 2023-11-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| AU2021368725A1 (en) * | 2020-10-30 | 2023-05-25 | Immusoft Corporation | Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents |
| CA3209779A1 (fr) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Therapie genique de ceroides-lipofuscinoses neuronales |
| WO2023087019A2 (fr) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions pour la réduction spécifique de drg de l'expression de transgènes |
| WO2023102517A1 (fr) | 2021-12-02 | 2023-06-08 | The Trustees Of The University Of Pennsylvania | Compositions et méthodes de traitement de la maladie de fabry |
| WO2023172975A1 (fr) * | 2022-03-08 | 2023-09-14 | University Of Massachusetts | Méthodes d'encapsulation de vaar |
| WO2023196893A1 (fr) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Compositions et méthodes de traitement d'un cancer du sein métastatique her2 positif et d'autres cancers |
| WO2023196892A1 (fr) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Immunisation passive avec des anticorps neutralisants anti-aav pour empêcher la transduction hors cible de vecteurs aav administrés par voie intrathécale |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6149909A (en) | 1995-06-23 | 2000-11-21 | Women's And Children's Hospital | Synthetic α-L-iduronidase and genetic sequences encoding same |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| WO1998010088A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 |
| AU4072499A (en) | 1998-05-13 | 1999-11-29 | Harbor-Ucla | Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| JP4827353B2 (ja) | 1999-08-09 | 2011-11-30 | ターゲティッド ジェネティクス コーポレイション | 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大 |
| US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| RU2196988C2 (ru) | 2000-04-19 | 2003-01-20 | Государственный новосибирский областной клинический диагностический центр | Способ диагностики мукополисахаридозов |
| NZ600121A (en) | 2001-11-13 | 2013-12-20 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| AU2002360291A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
| WO2004055157A2 (fr) | 2002-08-13 | 2004-07-01 | Whitley Chester B | Procedes d'utilisation de vecteurs pour traiter des troubles metaboliques |
| US7155804B2 (en) | 2003-09-17 | 2007-01-02 | Moog Inc. | Method of forming an electric motor |
| JP5054975B2 (ja) | 2003-09-30 | 2012-10-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス（ａａｖ）の同源系統群、配列、それらを含有するベクターおよびそれらの用途 |
| JP5702519B2 (ja) | 2005-04-07 | 2015-04-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ａａｖベクターの機能を上げる方法 |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| WO2007120542A2 (fr) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Bibliothèque de capsides aav et protéines de capsides aav |
| US20090062144A1 (en) | 2007-04-03 | 2009-03-05 | Nancy Lan Guo | Gene signature for prognosis and diagnosis of lung cancer |
| US9415121B2 (en) | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| US20130023033A1 (en) | 2010-03-29 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| EP2826860B1 (fr) | 2010-04-23 | 2018-08-22 | University of Massachusetts | Vecteurs AAV de ciblage du système nerveux central et leurs procédés d'utilisation |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| EP2394667A1 (fr) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vecteurs et séquences pour le traitement de maladies |
| ES2724800T3 (es) | 2011-02-17 | 2019-09-16 | Univ Pennsylvania | Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9 |
| RS60207B1 (sr) | 2011-04-22 | 2020-06-30 | Univ California | Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu |
| EP3444342B1 (fr) | 2012-07-11 | 2020-05-27 | Sangamo Therapeutics, Inc. | Compositions et procédés pour le traitement de maladies lysosomiale congénitale |
| WO2014125647A1 (fr) | 2013-02-18 | 2014-08-21 | 富士通オプティカルコンポーネンツ株式会社 | Dispositif photorécepteur |
| KR102346455B1 (ko) | 2013-03-15 | 2022-01-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ｍｐｓｉ 치료를 위한 조성물 및 방법 |
| KR20220119187A (ko) | 2013-05-15 | 2022-08-26 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
| EP3561062A1 (fr) | 2013-09-13 | 2019-10-30 | California Institute of Technology | Récupération sélective |
| PT3198018T (pt) | 2014-09-24 | 2021-02-24 | Hope City | Variantes dos vetores de vírus adenoassociados para edição do genoma de alta eficácia e métodos da mesma |
| EP3204503A1 (fr) | 2014-10-06 | 2017-08-16 | Arthrogen BV | Thérapie génique à base de virus adéno-associés |
| RS63927B1 (sr) | 2015-05-15 | 2023-02-28 | Regenxbio Inc | Povezani adenovirus za terapijsku isporuku u centralni nervni sistem |
| WO2017024204A1 (fr) | 2015-08-06 | 2017-02-09 | Academia Sinica | Enzyme spécifiquement conçue par ingénierie pour l'enzymothérapie substitutive |
| US20180236105A1 (en) | 2015-10-23 | 2018-08-23 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
| US11098286B2 (en) | 2015-12-11 | 2021-08-24 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV9 |
| ES2934848T3 (es) | 2015-12-11 | 2023-02-27 | Univ Pennsylvania | Método de purificación escalable para AAV8 |
| US11028372B2 (en) | 2015-12-11 | 2021-06-08 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAVRH10 |
| WO2017100674A1 (fr) | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Procédé de purification évolutif pour virus adéno-associé (aav) 1 |
| CA3010738A1 (fr) | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methodes et compositions pour le traitement d'une maladie neurologique |
| MA43968A (fr) | 2016-02-03 | 2018-12-12 | Univ Pennsylvania | Thérapie génique pour traiter la mucopolysaccharidose de type i |
| CA3068328A1 (fr) | 2017-07-06 | 2019-01-10 | The Trustees Of The University Of Pennsylvania | Therapie genique mediee par aav9 pour traiter la mucopolysaccharidose de type i |
-
2017
- 2017-02-02 MA MA043968A patent/MA43968A/fr unknown
- 2017-02-02 IL IL260959A patent/IL260959B1/en unknown
- 2017-02-02 BR BR112018015751A patent/BR112018015751A2/pt unknown
- 2017-02-02 SG SG11201806270XA patent/SG11201806270XA/en unknown
- 2017-02-02 AU AU2017215211A patent/AU2017215211C1/en active Active
- 2017-02-02 US US16/075,056 patent/US10973929B2/en active Active
- 2017-02-02 EP EP17706915.0A patent/EP3411488A1/fr active Pending
- 2017-02-02 WO PCT/US2017/016133 patent/WO2017136500A1/fr active Application Filing
- 2017-02-02 KR KR1020187025463A patent/KR20180121899A/ko unknown
- 2017-02-02 SG SG10201912758TA patent/SG10201912758TA/en unknown
- 2017-02-02 JP JP2018540838A patent/JP7360241B2/ja active Active
- 2017-02-02 CA CA3012195A patent/CA3012195A1/fr active Pending
-
2021
- 2021-03-15 US US17/201,301 patent/US20210228740A1/en not_active Abandoned
-
2023
- 2023-02-17 JP JP2023023041A patent/JP2023062088A/ja active Pending
- 2023-05-02 AU AU2023202680A patent/AU2023202680A1/en active Pending
- 2023-09-27 US US18/475,999 patent/US20240024510A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL260959A (en) | 2018-09-20 |
| AU2017215211B2 (en) | 2023-05-18 |
| US20240024510A1 (en) | 2024-01-25 |
| SG10201912758TA (en) | 2020-02-27 |
| AU2017215211A1 (en) | 2018-08-09 |
| EP3411488A1 (fr) | 2018-12-12 |
| WO2017136500A1 (fr) | 2017-08-10 |
| AU2023202680A1 (en) | 2023-07-13 |
| JP7360241B2 (ja) | 2023-10-12 |
| US10973929B2 (en) | 2021-04-13 |
| SG11201806270XA (en) | 2018-08-30 |
| CA3012195A1 (fr) | 2017-08-10 |
| JP2023062088A (ja) | 2023-05-02 |
| KR20180121899A (ko) | 2018-11-09 |
| BR112018015751A2 (pt) | 2019-02-05 |
| JP2019512005A (ja) | 2019-05-09 |
| AU2017215211C1 (en) | 2023-11-16 |
| IL260959B1 (en) | 2024-05-01 |
| US20210228740A1 (en) | 2021-07-29 |
| US20190038772A1 (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43968A (fr) | Thérapie génique pour traiter la mucopolysaccharidose de type i | |
| MA44874A (fr) | Thérapie génique pour traiter la mucopolysaccharidose de type ii | |
| MA50016A (fr) | Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i | |
| DK3262066T4 (da) | Genterapi | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| IL259762B (en) | Complement activity modulators | |
| HK1246672A1 (zh) | 補體活性的調節劑 | |
| ES2973101T3 (es) | Métodos para tratar proteinopatías | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
| MA47847A (fr) | Thérapie génique pour traiter la mucopolysaccharidose de type i | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| MA47173A (fr) | Thérapie génique pour traiter la mucopolysaccharidose de type ii | |
| HK1248595A1 (zh) | 改善視覺的基因療法 | |
| IL253231A0 (en) | Use of bgp15 to treat familial dysautonomia | |
| GB201521547D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201521541D0 (en) | New therapeutic uses of enzyme inhibitors | |
| TH1501004349A (th) | ยาสำหรับป้องกันหรือรักษาภาวะท้องผูก |